Connect with us

Health and Wellness

What Are Puberty Blockers? What Are the Benefits and Risks for Transgender Children?

Published

on

Puberty blockers are drugs that stop the body from producing estrogen and testosterone. In the clinic, they’re called gonadotropin-releasing hormone agonists (GnRHa).

If teens take these medications during puberty, the physical changes related to puberty are prevented. If these medications are stopped, the physical changes return.

Puberty blockers were used since the starting of the 80s in the treatment of precocious puberty in young children.

Since the Nineteen Nineties.Puberty blockers have also been utilized in transgender adolescents to stop the unwanted development of male or female physical changes that occur during puberty.

What advantages do transgender teens receive?

Many transgender children describe the anxiety about the undesirable physical changes that may occur during puberty, especially as puberty approaches.

For presumed females at birth, these undesirable changes include breast development and early periods. For presumed males at birth, these undesirable changes may include the development of a deeper voice, an Adam’s apple, facial hair, and a masculine construct.

Many of those physical changes are irreversible and cause not only Gender dysphoria but additionally misgendering. This is when transgender persons are mistakenly assigned the gender they were assigned at birth. Misgendering generally is a significant and lifelong the source of suffering.

Some transgender people will seek surgery to handle these unwanted irreversible changes. This may include chest masculinization, facial feminization, voice changes, or Adam’s apple reduction.

For young transgender people and their families, the most blatant advantages of using puberty blockers are: avoid unwanted changes that occur with puberty. It can even reduce misgendering and prevent the need for future surgeries.

Puberty blocking drugs may reduce misgendering.
Share

Several studies have evaluated the potential advantages of puberty blockers. Systematic review 2024 studies have provided consistent evidence that they’re effective in inhibiting puberty.

The study, which the review authors described as highest quality significantly improved psychological outcomes. Puberty blockers reduced suicidal thoughts and actions in transgender adolescents compared with those that didn’t use treatment.

When must you start using puberty blockers?

Puberty blockers can only be began once puberty has began. The age at which this happens varies greatly between individuals. To avoid unwanted physical changes, puberty blockers should ideally be began in early or middle adolescence.

However, many transgender adolescents were began on puberty blockers at the end of puberty and even after it had ended.

IN EnglandFor example, at the least 12 months of treatment with puberty blockers was previously mandatory for any transgender teen under 18 who wanted access to estrogen or testosterone. As a result, many young people began using puberty blockers long after puberty had ended.

One potential problem with starting puberty blockers after early or mid-puberty is that unwanted physical changes have already occurred, so no further profit must be expected from this treatment.

The last systematic review of puberty blockers noted that while many studies found improvements in psychological well-being, others found no difference. One possible explanation is that none of those studies considered the stage of adolescence at which treatment began.

Especially, a more recent study conducted at Harvard University evaluation was restricted to puberty blocker treatment in early and middle adolescence. Treatment was found to be related to significant reductions in anxiety, depression, and suicidal ideation.

Risk of Puberty Blockers for Transgender Teens

Puberty blockers are generally well tolerated. However, like every medical intervention, they can even cause undesirable effectsThis includes decreased bone density and fertility, and changes in adult growth.

When they begin after early or middle puberty, they usually tend to cause menopause-like unwanted effects, corresponding to hot flashes. This is as a result of a decrease in sex hormone production.

The girl looks warmly at her father
Puberty blocking drugs are generally well tolerated but can have potential unwanted effects.
Alena Ozerova/Shutterstock

There are also potential long-term effects of puberty blockers which are still being researched.

The brain matures significantly during adolescence. However, it’s unclear what effect puberty blockers can have on cognitive development. While the use of puberty blockers in early adolescence has not shown influence cognitive functioning, research on transgender teenagers are in progress.

Where are the randomized controlled trials of puberty blockers?

Randomized controlled trials are widely considered the gold standard for testing the effectiveness of medical interventions.

To date, there have been no randomized controlled trials of puberty blockers in transgender teens, leading some to call the treatment experimental. However, carrying out such hormonal intervention trials in transgender youth is problematic because it might be unethical to withhold treatment for research purposes.

In pediatric care, data from randomized controlled trials are sometimes lacking. more broadlySimilar research gaps apply to the use of puberty blockers in early puberty.

However, the politicization of transgender youth has meant that the use of puberty blockers in transgender adolescents has been judged by a unique standard.

How are puberty blockers accessed in several clinical situations?

IN United KingdomPuberty blockers will now only be available available for transgender teens through the National Health Service (NHS) as a part of a research effort, following the recommendations of the Cass Review, which checked out gender identity services available to children and young people through the NHS.

One of the primary criticisms of the review was that it didn’t consider the likely harms of denying hormone therapy to transgender teenagers.

In Australia, health experts also caution against comparing our healthcare system to the NHS and indicate that a lot of the recommendations in the review are consistent with practices currently utilized in Australian specialist gender equality services.

Puberty blockers in Australia can be found to transgender adolescents as a part of a comprehensive, team-based approach to gender-affirming care. This emphasizes holistic, individualized care that takes under consideration the young person’s stage of puberty while balancing potential advantages and risks.

This article was originally published on : theconversation.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending